Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.

about

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.BC094916 suppressed SP 2/0 xenograft tumor by down-regulating Creb1 and Bcl2 transcription

P2860

Q52663213-E4289EAC-8C8A-4F7F-A39E-36E90D88131D Q58741742-907D4BC5-9D1D-4E4A-BD77-21299E451431

P2860

Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.

Item

http://www.wikidata.org/entity/Q39158020

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@en

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@nl

type

Item

label

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@en

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@nl

prefLabel

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@en

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@nl

P1476

Renin-angiotensin-aldosterone ...... n dystrophic skeletal muscles.

@en

P2093

Jeovanna Lowe

http://www.w3.org/2001/XMLSchema#string

Jessica A Chadwick

http://www.w3.org/2001/XMLSchema#string

Jill A Rafael-Fortney

http://www.w3.org/2001/XMLSchema#string

Noah Weisleder

http://www.w3.org/2001/XMLSchema#string

Sayak Bhattacharya

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse

Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.

Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.

Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy

Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Circadian rhythms, the molecular clock, and skeletal muscle.

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial

P304

C155-C168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPCELL.00269.2016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

312

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27881412

http://www.w3.org/2001/XMLSchema#string

P932

5336592

http://www.w3.org/2001/XMLSchema#string

Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.

about

P2860

P2860

Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932